Xeris Pharmaceuticals (NSDQ:XERS) said last week that it launched a Phase I trial of its ready-to-use liquid glucagon in a closed-loop, dual-hormone artificial pancreas system.
Automated insulin delivery systems represent the latest advancement in diabetes management. But these technologies fall short of performing the tasks of a human pancreas – they deliver insulin, but they can’t co-deliver glucagon. Traditional dry-powder glucagon formulations must be used immediately, according to Xeris, or else they begin to degrade.
Get the full story at our sister site, Drug Delivery Business News.